₹134 Cr
₹-31 Cr
--
As on 22-Sep-2023 IST
₹-0.10
•
-0.37%
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Lasa Supergenerics
| -20.06 | 11.85 | 20.09 | -35.18 | -26.10 | 2.35 | -- |
|
S&P BSE Healthcare
| 20.54 | -0.92 | 10.55 | 20.23 | 12.28 | 12.24 | 11.52 |
|
S&P BSE Small Cap
| 28.11 | 4.28 | 13.75 | 26.74 | 35.95 | 18.64 | 21.05 |
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|
|
Lasa Supergenerics
| -50.95 | -18.77 | 354.84 | -43.44 | -84.13 |
|
S&P BSE Small Cap
| -1.80 | 62.77 | 32.11 | -6.85 | -23.41 |
|
S&P BSE Healthcare
| -12.10 | 20.87 | 61.45 | -3.55 | -5.89 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
No Review & Analysis are available.
The total asset value of Lasa Supergenerics Ltd. stood at ₹ 164 Cr as on 30-Jun-23
The share price of Lasa Supergenerics Ltd. is ₹26.900000 (NSE) and ₹26.730000 (BSE) as of 22-Sep-2023 IST. Lasa Supergenerics Ltd. has given a return of -26.1% in the last 3 years.
Lasa Supergenerics Ltd. has a market capitalisation of ₹ 134 Cr as on 22-Sep-2023. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Lasa Supergenerics Ltd. is 1.18 times as on 22-Sep-2023, a -0.64% premium to its peers’ median range of 3.28 times.
Since, TTM earnings of Lasa Supergenerics Ltd. is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Lasa Supergenerics Ltd. and enter the required number of quantities and click on buy to purchase the shares of Lasa Supergenerics Ltd..
Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products primarily in India. It offers API products comprising fenbendazole, toldimphos sodium, cyromazine, albendazole, riclabendazole, rafoxanide, ornidazole, ricobendazole, oxfendazole, closantel base, closantel sodium, nitroxynil, halquinol, and oxyclozanide, as well as 2,6-diiodo-4-nitrophenol; and other API products, such as anthelmintics. The company also provides animal feed ingredients, including calcium iodate; and reagents for therapeutic use comprising potassium iodide. It also exports its products. Lasa Supergenerics Limited was incorporated in 2016 and is based in Mumbai, India.
The promoter of Lasa Supergenerics Ltd. is OMKAR PRAVIN HERLEKAR. OMKAR PRAVIN HERLEKAR owns 53.65 per cent of the total equity. The chairman of the company is Omkar Pravin Herlekar , and the managing director is Omkar Pravin Herlekar..
The promoters of Lasa Supergenerics Ltd. have pledged 11.08% of the total equity as on Jun-23.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
8,148
|
|
|
8,069
|
|
|
7,910
|
|
|
7,585
|
| Lasa Supergenerics Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
-25.36
|
|
Return on capital employed(%)
|
--
|
|
Debt-to-equity ratio
|
0
|
|
Dividend yield(%)
|
0.94
|
No, TTM profit after tax of Lasa Supergenerics Ltd. was ₹-31 Cr.
No Review & Analysis are available.
₹133.92 Cr
₹131.25 Cr
₹-31.48 Cr
₹2.39 Cr
₹20.17 Cr
53.65%
Moderate
₹17.10 - 43.00
₹10.00
5,01,01,239
BSE: 540702, NSE: LASA
Mahad, Maharashtra
www.lasalabs.com
Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products primarily in India. It offers API products comprising fenbendazole, toldimphos sodium, cyromazine, albendazole, riclabendazole,... rafoxanide, ornidazole, ricobendazole, oxfendazole, closantel base, closantel sodium, nitroxynil, halquinol, and oxyclozanide, as well as 2,6-diiodo-4-nitrophenol; and other API products, such as anthelmintics. The company also provides animal feed ingredients, including calcium iodate; and reagents for therapeutic use comprising potassium iodide. It also exports its products. Lasa Supergenerics Limited was incorporated in 2016 and is based in Mumbai, India. Read more
Learn the principles, mindset and tools you need to become a successful Mutual Fund and Stock investor from the masters who have been doing this for decades.
Use India's most advanced investment tracker to track, analyse and get updates and insights on your investments.
Get an analysis of your portfolio along with actionable, general tips and insights, guidance on where to invest based on your goals, and experts' opinions on individual Mutual Funds and Stocks.
Value Research offers the most advanced and detailed data & analytics available on Mutual Funds and Stocks. Sign up and unlock the power yourself.
Unlimited access to advice from India's top experts
The most comprehensive analysis of funds and stocks in India
A holistic portfolio manager to help track all your investments easily
And much more, like guides, tools, webinars, videos and eBooks.
Share via Facebook 
Share via Twitter 
Share via LinkedIn 
Share this
Add Portfolio 